Session: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research
Method: As part of a larger, IRB-approved, retrospective clinical study, we collected clinical and laboratory data for children admitted to Intensive Care Units at Cincinnati Children’s Hospital and Medical Center on ECMO and anticoagulated with UFH or bivalirudin between January 16, 2018 and August 30, 2023. We performed cost analysis by identifying the total number of laboratory tests (CBC, aPTT, fibrinogen, AT3, UFH level, dTT, and free Hgb) ordered for patients during the first 5 days of ECMO and used the 2024 institutional list prices for each test.
Results: A total of 47 patients anticoagulated with UFH and 30 patients anticoagulated with bivalirudin were included for analysis. The average number of tests drawn in the bivalirudin group were decreased, specifically: complete blood count (UFH versus bivalirudin, 19.6 vs 17.7 tests, p=0.012), fibrinogen (18.0 vs 14.8, p=0.003), unfractionated heparin level (19.0 vs 7.1, p<0.001), and antithrombin (15.6 vs 6.3, p<0.001). The average number of monitoring labs per day of ECMO (UFH level for the UFH group and dTT for the bivalirudin group) was similar within the first five days of ECMO support – however, with UFH cost ($211) vs dTT ($126) and fewer antithrombin levels ($418) needed in the bivalirudin group, this represents further cost savings for bivalirudin-monitored patients. Finally, average monitoring cost per day was decreased in the bivalirudin group ($2164 vs $3226 in the UFH group).
Discussion: The dTT, previously demonstrated as superior to the aPTT for monitoring bivalirudin therapy, can be performed in clinical laboratories on an automated or semi-automated platform. Clinical guidelines at many institutions (including Extracorporeal Life Support Organization [ELSO] members) continue to use aPTT for bivalirudin monitoring with concerns for cost and lack of expertise/availability for dTT in their clinical laboratories; at our ELSO member institution, multiple daily aPTTs are ordered, even as dTT is clinically used for managing bivalirudin. Monitoring cost and blood sampling volume savings will be enhanced by reducing aPTT orders to only clinically necessary. Even so, these data demonstrate that bivalirudin monitoring by dTT in MCS is cost-efficient for the main laboratory parameters tested. Previous studies have reported decreased need for blood product transfusions and circuit changes with bivalirudin, with favorable or equivalent total costs in MCS patients. This work demonstrates that dTT monitoring of bivalirudin in pediatric patients during the first 5 days of ECMO is cost-efficient and potentially reduces total laboratory test/blood volume sampling.
Disclosures: No relevant conflicts of interest to declare.